Disitertide TFA
Based on 19 publication(s) in Google Scholar
Disitertide (P144) TFA is a peptidic transforming growth factor-beta 1 (TGF-β1) inhibitor specifically designed to block the interaction with its receptor. Disitertide TFA is also a PI3K inhibitor and an apoptosis inducer.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Formule: C68H109N17O22S2.xC2HF3O2
- Masse moléculaire:1580.82 (free acid)
-
Stockage:
Sealed storage, away from moisture and light.
Powder -80°C, 2 years , -20°C, 1 year* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Disitertide TFA
More- J Exp Clin Cancer Res. 2021 Feb 9;40(1):62. [Abstract]
- Cell Death Differ. 2021 Jan;28(1):219-232. [Abstract]
- Oncogene. 2019 Jun;38(23):4637-4654. [Abstract]
- Int J Surg. 2025 Jul 9. [Abstract]
- Int J Mol Med. 2019 May;43(5):2212-2220. [Abstract]
- Front Immunol. 2017 Feb 3:8:91. [Abstract]
- Biochem Pharmacol. 2026 Jul:249:117901. [Abstract]
- Life Sci. 2026 Mar 1:388:124173. [Abstract]
- Cells. 2019 Jun 25;8(6):635. [Abstract]
- Int Immunopharmacol. 2024 Nov 15:141:112778. [Abstract]
- Sci Rep. 2026 Feb 17;16(1):9447. [Abstract]
- Funct Integr Genomics. 2024 Jul 12;24(4):123. [Abstract]
- Acta Histochem. 2023 Feb;125(2):152010. [Abstract]
- Dig Dis Sci. 2025 May;70(5):1799-1812. [Abstract]
- Dig Dis Sci. 2021 Jun;66(6):1916-1927. [Abstract]
- Cancer Manag Res. 2018 Oct 10:10:4459-4470. [Abstract]
- Braz J Med Biol Res. 2026 Mar 30:59:e15172. [Abstract]
- J BUON. 2021 Mar-Apr;26(2):435-443. [Abstract]
- Eur Rev Med Pharmacol Sci. 2019 Aug;23(3 Suppl):9-16. [Abstract]
Customer Validation & Images
-
WB
Activité biologique
Disitertide (P144, 100 μg/mL) TFA suppresses the protein expression levels of PI3K and p-Akt, and induce the protein expression of Bax in MC3T3-E1 cells[2].
Disitertide (TGF-β1 inhibitor) TFA abrogates the MACC1-AS1 expression in GC cells, suggesting that targeting TGFβ signaling pathway may be a potential strategy to inhibit MSC-induced stemness and chemoresistance[3].
Disitertide (10 μg/mL to 200 μg/mL) TFA affects proliferation, induces apoptosis as well as anoikis in A172 and U-87 MG GBM cell lines[5].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Mouse embryo osteoblast precursor MC3T3-E1 cells.
-
Concentration:100 μg/mL.
-
Incubation Time:4 h.
-
Result:Significantly suppressed the protein expression levels of PI3K and p-Akt, and induce the protein expression of Bax in MC3T3-E1 cells compared with the miR-590 group.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Human hypertrophic scars were implanted in 60 nude mice[4].
-
Dosage:300 μg/mL was added the Lipogel.
-
Administration:Topical application daily administered.
-
Result:Successful shedding was achieved in 83,3% of the xenografts.
Chemical Information
-
Appearance Solid
-
Masse moléculaire 1580.82 (free acid)
-
Formule C68H109N17O22S2.xC2HF3O2
-
Color Off-white to light yellow
-
Synonyms
P144 TFA
-
Sequence
Thr-Ser-Leu-Asp-Ala-Ser-Ile-Ile-Trp-Ala-Met-Met-Gln-Asn
-
Sequence Shortening
TSLDASIIWAMMQN
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Sealed storage, away from moisture and light
Powder -80°C 2 years -20°C 1 year * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
Publications (19)
-
Journal Impact Factor
-
Most Recent
-
J Exp Clin Cancer Res
HOXA10 mediates epithelial-mesenchymal transition to promote gastric cancer metastasis partly via modulation of TGFB2/Smad/METTL3 signaling axis. [Abstract]2021 Feb 9;40(1):62. PMID: 33563300 -
Cell Death Differ
LINC00941 promotes CRC metastasis through preventing SMAD4 protein degradation and activating the TGF-β/SMAD2/3 signaling pathway. [Abstract]2021 Jan;28(1):219-232. PMID: 32737443
Disitertide TFA purchased from MedChemExpress. Usage Cited in: Cell Death Differ. 2021 Jan;28(1):219-232. [Abstract]
LINC00941-overexpressing cells treated with Disitertide (10 μM) shows increased mRNA and protein levels of ZO-1 and Ecadherin compared with controls. LINC00941-silenced cells show decreased mRNA and protein levels of ZO-1 and E-cadherin but increased mRNA and protein levels of Vimentin, Fibronectin, and Twist1.
-
Oncogene
MSC-regulated lncRNA MACC1-AS1 promotes stemness and chemoresistance through fatty acid oxidation in gastric cancer. [Abstract]2019 Jun;38(23):4637-4654. PMID: 30742067 -
Int J Surg
Distinct roles of HMOX1 on tumor epithelium and macrophage for regulation of immune microenvironment in ovarian cancer. [Abstract]2025 Jul 9. PMID: 40638251 -
Int J Mol Med
Upregulation of microRNA‑590 in rheumatoid arthritis promotes apoptosis of bone cells through transforming growth factor‑β1/phosphoinositide 3‑kinase/Akt signaling. [Abstract]2019 May;43(5):2212-2220. PMID: 30864698 -
Front Immunol
Ultraviolet B Inhibits IL-17A/TNF-α-Stimulated Activation of Human Dermal Fibroblasts by Decreasing the Expression of IL-17RA and IL-17RC on Fibroblasts. [Abstract]2017 Feb 3:8:91. PMID: 28217129 -
Biochem Pharmacol
Endothelial Foxp1 overexpression inhibits endothelial-to-mesenchymal transition via suppressing Notch pathway activation to attenuate valvular calcification in chronic kidney disease. [Abstract]2026 Jul:249:117901. PMID: 41839241 -
Life Sci
Galectin-9 in human trophoblast cells: Implications for maternal-fetal immune balance and pregnancy complications. [Abstract]2026 Mar 1:388:124173. PMID: 41544754 -
Cells
Activation of Slit2/Robo1 Signaling Promotes Tumor Metastasis in Colorectal Carcinoma through Activation of the TGF-β/Smads Pathway. [Abstract]2019 Jun 25;8(6):635. PMID: 31242633 -
Int Immunopharmacol
Renal denervation improves mitochondrial oxidative stress and cardiac hypertrophy through inactivating SP1/BACH1-PACS2 signaling. [Abstract]2024 Nov 15:141:112778. PMID: 39173402 -
Sci Rep
Bmscs loaded exosome hydrogel promotes the repair of rotator cuff injury in rats in vivo. [Abstract]2026 Feb 17;16(1):9447. PMID: 41703226 -
Funct Integr Genomics
TGF-β1-Induced LINC01094 promotes epithelial-mesenchymal transition in hepatocellular carcinoma through the miR-122-5p/TGFBR2-SAMD2-SMAD3 Axis. [Abstract]2024 Jul 12;24(4):123. PMID: 38992207 -
Acta Histochem
Low dose TGF-β1 can improve vohwinkel syndrome by promoting the proliferation of keratinocytes. [Abstract]2023 Feb;125(2):152010. PMID: 36738515 -
Dig Dis Sci
NFAT2 Induces Tumor Cell Proliferation and Metastasis by Acting as a Transcriptional Co-activator of the TGF-β1/SMAD Signaling Pathway and Inducing the Epithelial-Mesenchymal Transition in Liver Cancer. [Abstract]2025 May;70(5):1799-1812. PMID: 40038210 -
Dig Dis Sci
Mesenchymal Stem Cell-Derived Exosomal microRNA-3940-5p Inhibits Colorectal Cancer Metastasis by Targeting Integrin α6. [Abstract]2021 Jun;66(6):1916-1927. PMID: 32671583 -
Cancer Manag Res
SALL4 activates TGF-β/SMAD signaling pathway to induce EMT and promote gastric cancer metastasis. [Abstract]2018 Oct 10:10:4459-4470. PMID: 30349378 -
Braz J Med Biol Res
MMP9 regulates osteogenesis and MMP2 expression through the TGF-β1/SMAD2/3 signaling pathway in lipopolysaccharide-induced osteoblasts. [Abstract]2026 Mar 30:59:e15172. PMID: 41919892 -
J BUON
Activation of human hepatic stellate cells enhances the metastatic ability of hepatocellular carcinoma cells via up-regulation of interleukin-1β. [Abstract]2021 Mar-Apr;26(2):435-443. PMID: 34076990 -
Eur Rev Med Pharmacol Sci
Role of miR-21 in rats with proliferative diabetic retinopathy via TGF-β signaling pathway. [Abstract]2019 Aug;23(3 Suppl):9-16. PMID: 31389569
Solvant et solubilité
H2O : < 0.1 mg/mL (insoluble)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: 2.5 mg/mL; Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 2.5 mg/mL; Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Working solution concentration: 0.22 mg/mL
Pureté et documentation
-
Fiche technique (276 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Cindy Neuzillet, et al. Targeting the TGFβ pathway for cancer therapy. Pharmacol Ther. 2015 Mar;147:22-31. [Content Brief]
[2]. Jun Yang, et al. Upregulation of microRNA‑590 in rheumatoid arthritis promotes apoptosis of bone cells through transforming growth factor‑β1/phosphoinositide 3‑kinase/Akt signaling. Int J Mol Med. 2019 May;43(5):2212-2220. [Content Brief]
[3]. Wanming He, et al. MSC-regulated lncRNA MACC1-AS1 promotes stemness and chemoresistance through fatty acid oxidation in gastric cancer. Oncogene. 2019 Jun;38(23):4637-4654. [Content Brief]
[4]. Shan Shan Qiu, et al. Effect of P144® (Anti-TGF-β) in an "In Vivo" Human Hypertrophic Scar Model in Nude Mice. PLoS One. 2015 Dec 31;10(12):e0144489. [Content Brief]
[5]. Gabriel Gallo-Oller, et al. P144, a Transforming Growth Factor beta inhibitor peptide, generates antitumoral effects and modifies SMAD7 and SKI levels in human glioblastoma cell lines. Cancer Lett. 2016 Oct 10;381(1):67-75. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Disitertide TFA Related Classifications
HY-P0118A Related Classifications
Powered by Bioz